Ascendis Pharma A/S vs Equinix Inc — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Equinix Inc trades at $1,032.41 (market cap $101.87B). The key difference: Equinix Inc is far larger — about 6.1× Ascendis Pharma A/S's market cap, and Equinix Inc pays a 2% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EQIX | |
|---|---|---|
Market Cap | $16.67B | $101.87B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $1.12K |
52-Week Low | $189.74 | $726.09 |
Enterprise Value | $17.04B | $123.00B |
Dividend Yield | — | 2% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →